Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA

Key Points

• Stratos Wealth Partners boosted its stake in Zevra Therapeutics by 78.6% in Q4 to 409,000 shares (about $3.67M), representing roughly 0.73% of the company.
• Company insiders have been net sellers recently — 114,158 shares worth about $1.06M were sold in the last 90 days (insiders now own 2.40%), including notable reductions by Adrian W. Quartel and Joshua Schafer.
• ZVRA shares trade around $9.74 with a market cap near $572M and a PE of 7.32; analysts give a consensus rating of “Moderate Buy” and an average target price of $23.00.

Stratos Wealth Partners LTD. increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 78.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 409,000 shares of the company's stock after purchasing an additional 180,000 shares during the period. Stratos Wealth Partners LTD. owned 0.73% of Zevra Therapeutics worth $3,665,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after purchasing an additional 1,812 shares during the last quarter. Strs Ohio purchased a new stake in shares of Zevra Therapeutics in the 1st quarter valued at about $125,000. Creative Planning purchased a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at about $92,000. Rhumbline Advisers lifted its holdings in shares of Zevra Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company's stock valued at $733,000 after purchasing an additional 8,636 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at about $255,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $9.74 on Tuesday. The stock has a market capitalization of $571.84 million, a PE ratio of 7.32 and a beta of 0.89. Zevra Therapeutics, Inc. has a 52-week low of $6.19 and a 52-week high of $13.16. The stock's 50-day moving average price is $9.12 and its 200 day moving average price is $9.21. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40.

Insiders Place Their Bets

In other Zevra Therapeutics news, insider Adrian W. Quartel sold 4,533 shares of the business's stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $8.83, for a total transaction of $40,026.39. Following the transaction, the insider owned 9,723 shares in the company, valued at approximately $85,854.09. The trade was a 31.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joshua Schafer sold 10,500 shares of the business's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total value of $96,495.00. Following the transaction, the insider owned 62,278 shares in the company, valued at $572,334.82. The trade was a 14.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 114,158 shares of company stock worth $1,062,878. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright set a $26.00 price target on Zevra Therapeutics in a research report on Tuesday, December 30th. Wall Street Zen cut Zevra Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. BTIG Research assumed coverage on Zevra Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $23.00 price target on the stock. Weiss Ratings upgraded Zevra Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a research report on Tuesday, March 10th. Finally, Guggenheim set a $23.00 price target on Zevra Therapeutics and gave the company a "buy" rating in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Zevra Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $23.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.